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Purpose: Elevated C-reactive protein (CRP) is associated with poor prognosis in 
several tumor types. The purpose of this study was to investigate serum CRP as a 
prognostic marker in small cell lung cancer (SCLC). Materials and Methods: The 
pretreatment serum CRP level was measured in 157 newly diagnosed SCLC pa-
tients, and correlation between serum CRP level and other clinical parameters was 
analyzed. Multivariate analyses were performed to find prognostic markers using 
Cox’s proportional hazards model. Results: The initial CRP concentration was with-
in the normal range in 72 (45.9%) patients and elevated in 85 (54.1%) patients. 
There was a significant correlation between serum CRP level and the extent of dis-
ease (p<0.001), weight loss (p=0.029) and chest radiation (p=0.001). Median overall 
survival (OS) in the normal CRP group was significantly longer than with the high 
CRP group (22.5 months vs. 11.2 months, p<0.001). Extent of disease (p<0.001), 
age (p=0.025), and performance status (p<0.001) were additional prognostic factors 
on univariate analysis. On multivariate analysis, elevated serum CRP level was an 
independent prognostic factor for poor survival (HR=1.8; p=0.014), regardless of the 
extent of disease (HR=3.7; p<0.001) and performance status (HR=2.2; p<0.001). 
Conclusion: High level of CRP was an independent poor prognostic serum marker 
in addition to previously well-known prognosticators in patients with SCLC.   
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INTRODUCTION
Small cell lung cancer (SCLC), which accounts for 20-25% of all lung cancers, is 
highly sensitive to radiotherapy and chemotherapy. Traditionally, well-known 
prognostic factors of SCLC include extent of disease, performance status, and 
weight loss. Several laboratory factors, such as neuron-specific enolase (NSE), cy-
tokeratin-19 fragments (CYFRA 21-1), carcinoembryonic antigen, lactate dehy-
drogenase (LDH), and albumin have been studied to show additional independent 
prognostic value, however, the weights of their values are still controversial and 
require prospective validation.1
There have been numerous reports about the relationship between chronic inflam-
mation and cancer. The inflammatory cells and cytokines found in tumor highly like-
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were excluded. All patients received platinum-based combi-
nation chemotherapy, mostly with irinotecan or etoposide. 
Patients with limited disease underwent concurrent chemo-
radiation therapy including 5,400 cGy of thoracic radiation. 
Traditionally, the two-stage system of the Veteran’s Admin-
istration Lung Group was used to classify the patients. Lim-
ited disease is defined as disease confined to the ipsilateral 
chest within a single radiation field, and extensive disease 
was defined as disease beyond the ipsilateral hemithorax 
including malignant pleural or pericardial effusion or hema-
togenous metastasis. Contralateral mediastinal and ipsilat-
eral supraclavicular lymphadenopathy are classified as lim-
ited-stage, while contralateral hilar and supraclavicular 
lymphadenopathy are usually classified as extensive stage 
disease.25 Weight loss was recorded in kilograms (kg) and 
defined as more than 5 kg or 10% of baseline body weight 
loss during the past six months. Co-morbidity included the 
following conditions; hypertension, diabetes mellitus, cere-
brovascular disease, ischemic heart disease, asthma, chron-
ic obstructive lung disease, liver cirrhosis, and end stage re-
nal disease. Response Evaluation was performed with CT 
scan every two cycles, according to the Response Evaluation 
Criteria in Solid Tumors guidelines.26 
Pretreatment CRP values were measured from peripheral 
venous blood samples as part of the clinical routine, using an 
automatic nephelometer (Beckman Coulter image, Fullerton, 
CA, USA), according to the manufacturer’s instructions. 
Normal serum level was defined as ≤0.8 mg/dL by manufac-
turer’s manual. The correlation between serum CRP level 
and other categorical clinical variables was compared by 
Pearson’s chi-square test. Overall survival (OS) was mea-
sured from the date of diagnosis until the date of death or fi-
nal follow up. Progression-free survival (PFS) was defined as 
the time from the date of diagnosis until the date of tumor 
progression or death. The survival data were estimated using 
Kaplan-Meier curve and compared using the log-rank test. 
Multivariate analyses were performed to find prognostic 
markers using Cox’s proportional hazards model. A p-value 
of less than 0.05 was considered to be statistically significant. 
The study was approved by our institutional review board.  
RESULTS
 
Patients
A total of 157 patients were included in this study. Patient 
characteristics are summarized in Table 1. Fifty-nine pa-
ly to contribute to tumor growth, progression, and immune-
suppression compared to cope with an effective host anti-
tumor response.2-4 In fact, about 15% of cancers are initiated 
by chronic inflammation or infection such as helicobacter py-
lori, hepatitis virus, Epstein-Barr virus, and other bacteria. 
Persistent infection of the host induces chronic inflammation, 
and inflammatory cells induce DNA damage in proliferating 
cell, by generating reactive oxygen and nitrogen species.3 
Furthermore, it is well demonstrated by laboratory research 
that pro-inflammatory cytokines could promote tumor 
growth and metastasis by altering tumor cell biology and ac-
tivating stromal cells in the tumor microenvironment.3,5,6
C-reactive protein (CRP) is a nonspecific serum marker 
of acute-phase inflammatory response, and it is produced 
by hepatocytes which are regulated by interleukin (IL)-6.4,7 
Several possible mechanisms have been postulated for the 
relationship between CRP and cancers; first, tumor growth 
can cause tissue inflammation, hence increasing CRP level. 
Second, CRP could be an indicator of an immune response 
to tumor antigens. Third, cancer cells could increase the 
production of inflammatory cytokines, which could induce 
high CRP concentration in cancer patients.4 Many studies 
showed the elevation of pretreatment CRP to be a signifi-
cant prognostic parameter in patients with esophageal can-
cer,8-10 hepatocellular carcinoma,11 colorectal cancer,12-14 re-
nal cell cancer,15-17 ovarian cancer,18 and non-small cell lung 
cancer (NSCLC).19-23 Furthermore, we recently reported an 
association between preoperative serum CRP levels and 
pathologic parameter such as tumor size and lymphovascu-
lar invasion in patients with NSCLC.24       
At present, little is known about the relevance of inflam-
matory markers to survival in SCLC. In this study, we evalu-
ated the relationship between CRP and SCLC, and investi-
gated CRP as a potential prognostic serum marker in patients 
with SCLC.
MATERIALS AND METHODS
　　　
We reviewed patients who had histologically confirmed 
SCLC and received chemotherapy at the Yonsei Cancer Cen-
ter, Seoul, Korea. Retrospective analysis was performed re-
garding initial serum CRP concentration, age, gender, ex-
tent of disease, weight loss, Eastern Cooperative Oncology 
Group (ECOG) performance status at first presentation, 
smoking history, co-morbidity, best response to chemother-
apy, and survival. Patients with active concurrent infection 
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chemotherapy in combination with irinotecan (63.1%), eto-
poside (31.8%), or other agents (5.1%) according to physi-
cians’ choice.
Serum CRP and patient characteristics
The initial CRP concentration in 72 patients (45.9%) was 
within the normal range, and elevated in 85 patients (54.1%). 
tients (37.6%) had limited disease and 98 patients (62.4%) 
had extensive disease. The median age was 65 years (range, 
46-82), and majority of patients were male (n=140; 89.2%). 
Most of the patients (n=127; 79%) had good performance 
status (ECOG 0-1), and only 29 patients (18.5%) had sig-
nificant weight loss. Ten patients (6.4%) had never smoked. 
All patients included in this study underwent platinum-based 
Table 1. Baseline Characteristics
Characteristics
Overall (%) 
(n=157)
Serum CRP
Normal  (n=72) Elevated  (n=85) p value*
Stage
    Limited   59 (37.6) 39 (54.2)  20 (23.5) <0.001
    Extensive   98 (62.4) 33 (45.8)  65 (76.5)
Age, median (range)     65 (46-82)
    <65   72 (45.9) 32 (44.4)  40 (47.1) 0.743
    ≥65   85 (54.1) 40 (55.6)  45 (52.9)
Gender
    Male 140 (89.2) 61 (84.7)   79 (92.9) 0.099
    Female   17 (10.8) 11 (15.3)  6 (7.1)
Performance status
    ECOG 0-1 124 (79) 60 (83.3)  64 (75.3) 0.218
    ECOG 2 33 (21) 12 (16.7)  21 (24.7)
Weight loss
    No 128 (81.5) 64 (88.9)  64 (75.3) 0.029
    Yes   29 (18.5)   8 (11.1)  21 (24.7)
Smoking
    Never 10 (6.4) 7 (9.7)  3 (3.6) 0.153
    Ever 146 (93.6) 65 (90.3)  81 (96.4)
Co-morbidity†
    No   52 (33.1) 19 (26.4)  33 (38.8) 0.099
    Yes 105 (66.9) 53 (73.6)  52 (61.2)
WBC
    Normal   72 (45.9) 40 (52.6)  36 (42.4) 0.099
    High   85 (54.1) 32 (44.4)  49 (57.6)
Chemotherapy in combination with platinum‡
    Irinotecan   99 (63.1) 48 (66.7)  51 (60.1) 0.575
    Etoposide   48 (30.6) 19 (26.4)  29 (34.1)
    Others§ 10 (6.4) 5 (6.9)  5 (5.9)
Chest-radiation  
    No 100 (63.7) 36 (50.0)  64 (75.3) 0.001
    Yes   57 (36.3) 36 (50.0)  21 (24.7)
Treatment response
    Responder 104 (66.3) 52 (76.5)  52 (65.8) 0.157
    Non-responder   33 (27.4) 16 (23.5)  27 (34.2)
    Non-evaluable 10 (6.3)
ECOG, Eastern Cooperative Oncology Group; CRP, C-reactive protein; WBC, white blood cell count.
*Chi-squre test between normal CRP and elevated CRP group.
†Co-morbidity, hypertension, diabetes mellitus, cerebrovascular disease, ischemic heart disease, asthma, chronic obstructive lung dis-
ease, liver cirrhosis, and end stage renal disease (severity was not specified).
‡Platinum, cisplatin or carboplatin.
§Others, ifosfamide, topotecan, or belotecan.
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65.8%; p=0.157). With a median follow-up duration of 9.3 
months (range, 0.3-62.7), median PFS was 9.3 months 
[95% CI, 7.6-11.1], and median OS was 13.7 months (95% 
CI, 8.9-18.6). The median PFS and OS in the normal CRP 
group was significantly longer than with high CRP group 
(PFS, 11.0 months vs. 7.5 months; p=0.009; OS, 22.5 
months vs. 11.2 months, p<0.001) (Figs. 1 and 2). Addition-
ally, the extent of disease (23.0 months vs. 10.2 months, 
p<0.001), age (19.1 months vs. 12.5 months, p=0.026), per-
formance status (18.4 months vs. 5.3 months, p<0.001), 
and chemo-responsiveness (22.2 months vs. 4.9 months, 
p<0.001) were statistically significant factors in univariate 
analysis (Table 2). However, weight loss was not statistical-
ly significant for survival in univariate analysis (p=0.17).
In multivariate Cox regression model (Table 3), elevated 
CRP level was an independent prognostic marker for poor 
survival (HR=1.8, 95% CI, 1.1-2.9; p=0.014), regardless of 
extensive disease (HR=3.7; p<0.001) and poor perfor-
mance status (HR=2.2; p<0.001). 
DISCUSSION
To our best knowledge, this is the first report to evaluate the 
clinical usefulness of serum CRP for predicting survival of 
SCLC patients. In the multivariate analysis, pre-treatment 
serum CRP was revealed as a significant prognostic marker 
of SCLC, together with other well-known factors, such as 
stage and performance status. 
The mean value of serum CRP prior to treatment was 
4.7±7.6 mg/dL; 0.3±0.2 mg/dL in the normal CRP group and 
8.4±8.8 mg/dL in the high CRP group. Serum CRP level was 
significantly associated with the extent of disease (p<0.001), 
chest radiation (p=0.001) and weight loss (p=0.029), but two 
groups of extensive disease (limited vs. extensive) and group 
who received chest radiation or not showed almost same 
composition. 
Tumor response and survival
There was a trend for patients in the normal CRP group to-
ward higher response rate to chemotherapy (76.5% vs. 
Table 2. Univariate Analysis of Survival
Variables Median survival time (95% confidence interval) p value
Age <65   19.133 (11.868-26.399)   0.025 
　 ≥65   12.467 (10.386-14.547)
Performance status ECOG 0-1   18.400 (13.818-22.982) <0.001
　 ECOG ≥2 5.300 (1.484-9.116)
Stage Limited   23.000 (21.998-24.002) <0.001
　 Extensive 10.167 (8.106-12.228)
CRP Normal   22.533 (18.918-26.149) <0.001
　 Elevated 11.167 (9.373-12.960)
CRP, C-reactive protein.
Table 3. Factors Independently Affecting Overall Survival
Variable p value* Hazard ratio (95% confidence interval)
Serum CRP   0.014 1.803 (1.129-2.877)
Performance status <0.001 2.226 (1.427-3.474)
Extent of disease <0.001 3.660 (1.129-2.877)
CRP, C-reactive protein.
*Multivariate analysis by Cox's regression.
Fig. 1. Kaplan-Meier survival curve for overall survival in patients with nor-
mal CRP and elevated CRP group. CRP, C-reactive protein.
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Brekel, et al.37 reported that hypermetabolism and weight 
loss are related to enhanced inflammatory response in SCLC 
patients. In addition, several studies showed that acute phase 
response is involved in the pathogenesis of cancer cachex-
ia.38,39 We also found that extensive disease was associated 
with high serum CRP level, possibly demonstrating that large 
tumor burden is likely to increase inflammatory cytokines, 
such as IL-1, IL-2, tumor necrosis factor-alpha, and interfer-
on-gamma,2,3 which stimulates CRP production.18 
In terms of response, the relationship between serum CRP 
and response was not clear. It is highly possible that pre-treat-
ment serum CRP was not sufficient for predicting chemo-re-
sponse. Therefore, it is more reasonable to monitor serial 
serum CRP level, including not only pre-treatment but also 
during and after the treatment. Milroy, et al.40 demonstrated 
that acute phase response during chemotherapy might have 
a potential for predicting chemo-response in SCLC since 
chemo-sensitive tumors might result in tumor necrosis, there-
by inducing an acute phase reaction, and significant reduc-
tion in the level of CRP was observed after chemotherapy.41 
As for prognosis, elevated serum CRP was associated 
with reduced OS and PFS, apart from all clinically estab-
lished prognosticators. This result suggests that it might be 
a useful marker to define a subset of patients with bad prog-
nosis who require intensive treatment. For example, patients 
with higher pretreatment CRP within the same stage require 
more enhanced systemic chemotherapy than lower CRP 
group patients. In the present study, we found a trend be-
tween serum CRP level and survival within each stage: ED 
with high serum CRP group showed relatively shorter OS 
In various types of malignancy, clinical decision making 
before treatment is generally based on established clinical 
and histopathologic prognosticators. The knowledge of prog-
nostic factors, therefore, is important, so that it allows to clas-
sify patients who are candidates for newest intensive treat-
ment. Traditionally, two-stage system, performance status, 
and weight loss have been key prognostic factors in SCLC 
patients.1,27 Other prognostic variables, such as gender and 
age, have also been well-known as prognostic factors for 
SCLC, even though some controversies remain.1,28 Simple 
biochemical tests or serum markers are also important, and 
numerous studies showed that NSE, CYFRA 21-1, and 
LDH are promising prognostic factors.29-36 
Serum CRP levels, measurement of which is relatively 
inexpensive and easy to quantify in daily clinical practice, 
can be elevated in various acute and chronic benign condi-
tions such as cardiovascular disease, type 2 DM, arthritis, 
inflammatory bowel disease, trauma, and transplant rejec-
tion.4,24 In this study, patients with co-morbidity were 66.9% 
of all patients, however, we failed to observe any correla-
tion between CRP levels and co-morbidity (Table 1). As stat-
ed above, there have been many efforts to investigate the 
relationship between serum CRP and prognosis in several 
types of cancer. In NSCLC, preoperative CRP level provid-
ed prognostic information and was associated with patho-
logic tumor size and lympho-vascular invasion.21,23,24 In he-
patocellular carcinoma, the correlation of preoperative CRP 
level with tumor size and portal vein invasion was found, 
and CRP level was an independent indicator of poor prog-
nosis and early recurrence.11 In ovarian cancer, preoperative 
CRP was an independent prognostic marker associated 
with stage and postoperative residual tumor mass.18 In renal 
cell carcinoma (RCC), serum CRP was significantly associ-
ated with RCC-specific mortality.15 In esophageal cancer, 
preoperative high CRP level was associated with tumor 
progression and poor survival.8-10 Finally, in colorectal cancer, 
preoperative elevation of CRP level was an indicator of ma-
lignant potential of tumors such as liver metastasis, perito-
neal carcinomatosis, lymph node metastasis, and vascular 
invasion, as well as a predictor of poor prognosis.12,14 Until 
now, however, a few data showed the relationship between 
CRP and treatment outcomes in small cell lung cancer.  
In our study, a positive correlation between CRP and 
weight loss was observed. This is consistent with previous 
studies, which showed that systemic inflammatory response 
is associated with increase in resting energy expenditure and 
loss of lean tissue in patients with lung cancer: Staal-van den 
Fig. 2. Kaplan-Meier survival curve for progression-free survival in patients 
with normal CRP and elevated CRP group. CRP, C-reactive protein.
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2004;279:48487-90.
8. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of 
preoperative C-reactive protein as a parameter of the perioperative 
course and long-term prognosis in squamous cell carcinoma and 
adenocarcinoma of the oesophagus. World J Gastroenterol 
2006;12:3746-50.
9. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative ele-
vation of serum C-reactive protein as an indicator of prognosis in 
esophageal carcinoma. Am J Surg 2001;182:197-201.
10. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, 
Aoki T, et al. Elevation of preoperative serum C-reactive protein 
level is related to poor prognosis in esophageal squamous cell car-
cinoma. J Surg Oncol 2003;83:248-52.
11. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Ka-
wasaki K, et al. The impact of preoperative serum C-reactive pro-
tein on the prognosis of patients with hepatocellular carcinoma. 
Cancer 2005;103:1856-64.
12. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, 
Horgan PG, et al. Preoperative but not postoperative systemic in-
flammatory response correlates with survival in colorectal cancer. 
Br J Surg 2007;94:1028-32.
13. Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N. 
Preoperative plasma plasminogen activator inhibitor type-1 and 
serum C-reactive protein levels in patients with colorectal cancer. 
The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 
2000;7:617-23.
14. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance 
of preoperative elevation of serum C-reactive protein as an indica-
tor for prognosis in colorectal cancer. Am J Surg 1998;176:335-8.
15. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, 
Gallina A, et al. C-reactive protein is an informative predictor of 
renal cell carcinoma-specific mortality: a European study of 313 
patients. Cancer 2007;110:1241-7.
16. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relation-
ship between the preoperative systemic inflammatory response 
and cancer-specific survival in patients undergoing potentially cu-
rative resection for renal clear cell cancer. Br J Cancer 2006;94: 
781-4.
17. Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, 
et al. Predictive values of acute phase reactants, basic fetoprotein, 
and immunosuppressive acidic protein for staging and survival in 
renal cell carcinoma. Urology 2001;58:161-4.
18. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, 
et al. Serum C-reactive protein as independent prognostic variable 
in patients with ovarian cancer. Clin Cancer Res 2008;14:710-4.
19. Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDon-
ald N, Kasymjanova G, et al. Flexible modeling improves assess-
ment of prognostic value of C-reactive protein in advanced non-
small cell lung cancer. Br J Cancer 2010;102:1113-22.
20. Koch A, Fohlin H, Sörenson S. Prognostic significance of C-reac-
tive protein and smoking in patients with advanced non-small cell 
lung cancer treated with first-line palliative chemotherapy. J Tho-
rac Oncol 2009;4:326-32.
21. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto 
Y, et al. Preoperative serum C-reactive protein level in non-small 
cell lung cancer. Anticancer Res 2007;27:3001-4.
22. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. 
Correlation of C-reactive protein with survival and radiographic 
response to first-line platinum-based chemotherapy in advanced 
non-small cell lung cancer. Onkologie 2008;31:665-70.
than ED with low serum CRP group (mean OS for high CRP 
group vs. low CRP group, 19.1 months vs. 23.2 months; 
p=0.062). 
The mechanism by which an inflammatory response is 
evoked by SCLC is not yet clear. One possible mechanism 
is coexisting pulmonary infection (or obstructive pneumo-
nia), which could increase white blood cell counts (WBC), 
subsequently increasing pro-inflammatory cytokine CRP 
concentration. In the current study, therefore, we evaluated 
the correlation between WBC and CRP, however, failed to 
find any significant correlations (pearson correlation coeffi-
cient=0.140; p=0.099). This result might explain why in-
fection is not the main stimulus to the increased CRP. The 
other possibility is that pro-inflammatory cytokines are pro-
duced by tumor necrosis or local tissue damage which is 
caused by the tumor-host cell interaction, however, we are 
not certain whether those cytokines are produced directly 
by tumors. 
In conclusion, we suggest that pre-treatment serum CRP 
could be used as a prognostic marker in SCLC patients, and 
it might complement the prognostic value of stage and per-
formance status. However, the association between CRP and 
survival outcome might require further investigation, and our 
result should await internal or external validation before be-
ing used in clinical practice, because of the limitations inher-
ent to retrospective study with a small sample size. 
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